Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001549595-25-000044
Filing Date
2025-03-13
Accepted
2025-03-13 16:07:26
Documents
3
Period of Report
2025-03-11

Document Format Files

Seq Description Document Type Size
1 FORM 3 wk-form3_1741896439.html 3  
1 FORM 3 wk-form3_1741896439.xml 3 2951
2 EX-24 powerofattorneybaynes-co.htm EX-24 4370
3 GRAPHIC powerofattorneybaynes-co001.jpg GRAPHIC 226790
  Complete submission text file 0001549595-25-000044.txt   321345
Mailing Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 (415) 660-5320
Nurix Therapeutics, Inc. (Issuer) CIK: 0001549595 (see all company filings)

EIN.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O RETROPHIN, INC. 12255 EL CAMINO REAL, SUITE 250 SAN DIEGO CA 92130
Business Address
Baynes Roy D. (Reporting) CIK: 0001680739 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39398 | Film No.: 25735784